- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03747107
Pharmacist and Data Driven Quality Improvement in Primary Care (P-DQIP)
P-DQIP is an intervention to improve prescribing safety in primary care. The 'intervention' is a health board quality improvement programme that will be implemented across all practices in one National Health Service (NHS) board in Scotland (Tayside), and comprises the following components:
i. Case finding of patients with drug therapy risks via the P-DQIP informatics tool ii. Decision support for clinicians when conducting medication reviews via the P-DQIP informatics tool iii. Support from practice pharmacists in reviewing and managing targeted patients iv. Ongoing performance feedback via the P-DQIP informatics tool v. Promotion of the P-DQIP tool and intervention among general practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
Study Overview
Detailed Description
P-DQIP is an intervention to improve prescribing safety in primary care. The 'intervention' is a health board quality improvement programme that will be implemented across all practices in NHS Tayside. The study is therefore a service evaluation of an NHS Tayside-led initiative, which comprises the following components:
i. Case finding. The P-DQIP informatics tool will be added to medicines management software (the Scottish Therapeutics Utility), which is already installed in all general practices in NHS Scotland. The P-DQIP tool can be accessed by General Practitioners (GPs) and other clinicians in the practice including Health Board employed primary care pharmacists 'attached' to practices. The core of the tool is a set of indicators of high-risk prescribing to identify patients at high risk of drug related harm. The indicators have been developed by The Scottish Government's Polypharmacy working group.
ii. Decision support. The P-DQIP tool provides structured information on patients' medical and medication histories and highlights specific drug therapy risks for consideration by the reviewing clinician. All decision making remains at the discretion of the reviewing clinician.
iii. Pharmacist support. Teams of practice pharmacists working in practices within the same locality will be invited to participate in a half-day workshop, in which they will be trained on the use of the P-DQIP informatics tool. A total of 8 to 12 workshops will be conducted. The workshop will be facilitated by the P-DQIP project team. As part of the workshop, locality pharmacist teams will be encouraged to plan the P-DQIP work and to agree targets. They will be instructed to introduce the P-DQIP pogramme in a stepwise fashion, targeting patients at risk of bleeding and hypoglycaemia first.
iv. Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on the number of reviews conducted and the numbers of patients with targeted high-risk prescribing via the P-DQIP informatics tool.
v. Promotion of the P-DQIP tool and intervention among GP practices. GP clusters will be offered a visit by the lead pharmacist for the programme, who will provide background and rationale for the P-DQIP programme, demonstrate the functionalities of the P-DQIP informatics tool and encourage collaboration in reviewing and managing targeted drug therapy risks with pharmacists.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Scotland
-
Dundee, Scotland, United Kingdom, DD2 4BF
- NHS Tayside
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- General practices in NHS Tayside, who use the Vision electronic medical record software and agree to the extraction of data from medical records for monitoring and evaluation purposes
Exclusion Criteria:
- General practices using electronic medical record software other than Vision
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Initially targeted drug therapy risks in patients aged 75 years or older
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P001 to P011; Numerator definition: No. of denominator patients meeting one or more numerator definitions as specified under 'Other Pre-specified Outcomes' P001 to P011
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All targeted drug therapy risks in patients aged 75 years or older (patient count)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P001 to P046; Numerator definition: No. of denominator patients meeting one or more numerator definitions as specified under 'Other Pre-specified Outcomes' P001 to P046
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
All targeted drug therapy risks in patients aged 75 years or older (indicator count)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P001 to P046; Numerator definition: No. of indicators specified under 'Other Pre-specified Outcomes' P001 to P046 triggered by denominator patients
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Initially targeted drug therapy risks in younger patients
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged <75 years meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P001 to P011; Numerator definition: No. of denominator patients meeting one or more numerator definitions as specified under 'Other Pre-specified Outcomes' P001 to P011;
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
All targeted drug therapy risks in younger patients (patient count)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged <75 years meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P001 to P046; Numerator definition: No. of denominator patients meeting one or more numerator definitions as specified under 'Other Pre-specified Outcomes' P001 to P046
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
All targeted drug therapy risks in younger patients (indicator count)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged <75 years meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P001 to P046; Numerator definition: No. of indicators specified under 'Other Pre-specified Outcomes' P001 to P046 triggered by denominator patients
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
'Ongoing' versus 'new' drug therapy risks ('Ongoing')
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older meeting one or more denominator definitions specified under 'Other Pre-specified Outcomes' P001 to P011, who have met one or more numerator definitions specified under 'Other Pre-specified Outcomes' P001 to P011 in the previous 57 to 364 days; Numerator definition (Old): No. of denominator patients meeting one or more numerator definitions specified under 'Other Pre-specified Outcomes' P001 to P011
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
'Ongoing' versus 'new' drug therapy risks ('New')
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older meeting one or more denominator definitions specified under 'Other Pre-specified Outcomes' P001 to P011, who have NOT met any numerator definitions specified under 'Other Pre-specified Outcomes' P001 to P011 in the previous 57 to 364 days; Numerator definition: No. of denominator patients meeting one or more numerator definitions specified under 'Other Pre-specified Outcomes' P001 to P011
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Electrolyte disturbances
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged <75 years meeting one or more denominator definitions as specified under 'Other Pre-specified Outcomes' P047 to P050; Numerator definition: No. of indicators specified under 'Other Pre-specified Outcomes' P047 to P050 triggered by denominator patients
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Related unscheduled care events (1) - Bleeding
Time Frame: Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older; Numerator definition: No. of denominator patients who had an unscheduled care event with bleeding in the previous 84 days
|
Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Related unscheduled care events (2) - Hypoglycaemia, falls, fractures
Time Frame: Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older; Numerator definition: No. of denominator patients who had an unscheduled care event with hypoglycaemia, a fall or a fracture in the previous 84 days
|
Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Related unscheduled care events (3) - Any potentially drug related events
Time Frame: Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older; Numerator definition: No. of denominator patients who had an unscheduled care event in the previous 84 days with any of the following: Hypoglycaemia, fall, fracture, bleeding, heart failure, bradycardia, acute kidney injury, constipation, dehydration, hyperkalaemia, hyponatraemia, urinary retention, delirium) in the previous 84 days
|
Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Unrelated unscheduled care events
Time Frame: Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Denominator definition: No. of patients aged 75 years or older; Numerator definition: No. of denominator patients who had an unscheduled care event in the previous 84 days with an unrelated ambulatory care sensitive admission (Appendicitis, pancreatitis, cholecystitis, cancer, cellulitis)
|
Measured at intervals of 12 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Individual indicators (P001)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P001 - Denominator definition: No. of patients aged 75 and older; Numerator definition: No. of denominator patients with any non-topical non-steroidal anti-inflammatory drug (NSAID) issued in last 56d and NO gastro-protection issued in last 84d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P002)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P002 - Denominator definition: No. of patients aged 65 to 74 and gastrointestinal ulcer or issued an antiplatelet, oral anticoagulant or oral corticosteroid in last 56d; Numerator definition: No. of denominator patients with any non-topical NSAID issued in last 56d and NO gastro-protection issued in last 84d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P003)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P003 - Denominator definition: No. of patients aged 65 or older and aspirin issued in last 84d; Numerator definition: No. of denominator patients with clopidogrel issued in last 56d and NO gastro-protection issued in last 84d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P004)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P004 - Denominator definition: No. of patients with previous gastrointestinal ulcer; Numerator definition: No. of denominator patients with antiplatelet issued in last 56d and NO gastro-protection issued in last 84d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P005)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P005 - Denominator definition: No. of patients with an oral anticoagulant issued in last 84d; Numerator definition: No. of denominator patients with an antiplatelet issued in last 56d and NO gastro-protection issued in last 84d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P006)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P006 - Denominator definition: No. of patients with any of the following: Chronic kidney disease (CKD) stage 4 or 5 or latest estimated glomerular filtration rate (eGFR)<30ml/min (in previous 364 days); Numerator definition: No. of denominator patients with direct thrombin inhibitor issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P007)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P007 - Denominator: One of the following: CKD stage 5 or latest eGFR showing eGFR<15ml/min (in previous 364d); Numerator: Factor Xa inhibitor issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P008)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P008 - Denominator definition: No. of patients with an oral anticoagulant issued in last 84d; Numerator definition: No. of denominator patients with latest SBP>160 or latest DBP>100 BP (in previous 364 days)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P009)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P009 - Denominator definition: No. of patients with insulin issued in last 84d; Numerator definition: No. of denominator patients with no glucose test strips issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P010)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P010 - Denominator definition: No. of patients with diabetes type 2 and aged 75 or older or dementia; Numerator definition: No. of denominator patients with insulin or an oral hypoglycaemic drug other than metformin issued in last 56d and last glycated haemoglobin (HbA1c)<53 (7.0%) (in previous 364d)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P011)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P011 - Denominator definition: No. of patients Diabetes type 2 and aged 65 to 74 without dementia; Numerator definition: No. of denominator patients with insulin or an oral hypoglycaemic drug other than metformin issued in last 56d and last HbA1c<48 (6.5%) (in previous 364d)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P012)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P012- Denominator definition: No. of patients with an oral nitrate or nicorandil issued in last 84d; Numerator definition: No. of denominator patients with phosphodiesterase type-5 inhibitor issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P013)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P013- Denominator definition: No. of patients with heart failure; Numerator definition: No. of denominator patients with a glitazone issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P014)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P014- Denominator definition: No. of patients heart failure; Numerator definition: No. of denominator patients with any non-topical NSAID issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P015)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P015- Denominator definition: No. of patients with heart failure or issued a beta blocker in the previous 84d; Numerator definition: No. of denominator patients with verapamil or diltiazem issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P016)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P016- Denominator definition: No. of patients with heart failure without atrial fibrillation, CKD stage ≥3, latest eGFR<60ml/min (in previous 365 days) or verapamil issued in last 84d; Numerator definition: No. of denominator patients with digoxin tablets >125mcg strength issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P017)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P017- Denominator definition: No. of patients with beta blocker, acetylcholine esterase inhibitor or digoxin issued in last 84d; Numerator definition: No. of denominator patients with last pulse <60bpm
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P018)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P018- Denominator definition: No. of patients with CKD stage 5 or latest eGFR<10ml/min (in previous 365d); Numerator definition: No. of denominator patients with colchicine issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P019)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P019- Denominator definition: No. of patients with methotrexate issued in last 84d; Numerator definition: No. of denominator patients with methotrexate 2.5mg strength issued and methotrexate 10mg strength issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P020)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P020- Denominator definition: No. of patients with methotrexate issued in last 84d; Numerator definition: No. of denominator patients with trimethoprim issued in last 56d and trimethoprim issued in last 57 to 112 days
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P021)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P021- Denominator definition: No. of patients with one or more of the following risk factors for Acute Kidney Injury (AKI):
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P022)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P022- Denominator definition: No. of patients with CKD stage 4 or 5 or latest eGFR <30 ml/min (in previous 365 days) or ACEI or ARB issued in last 84d; Numerator definition: No. of denominator patients with potassium salt issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P023)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P023- Denominator definition: No. of patients with angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) issued in last 84d; Numerator definition: No. of denominator patients with ACEI and ARB issued in previous 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P024)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P024- Denominator definition: No. of patients with ACEI or ARB issued in last 84d and no history of CKD stage 4 or 5 and latest eGFR >=30 ml/min or unknown (in previous 364d); Numerator definition: No. of denominator patients with potassium sparing diuretic and aliskiren issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P025)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P025- Denominator definition: No. of patients CKD stage 4 or 5 or latest eGFR <30 ml/min (in previous 364d); Numerator definition: No. of denominator patients with potassium sparing diuretic or aliskiren issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P026)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P026- Denominator definition: No. of patients with CKD stage 4 or 5 or latest eGFR <30 ml/min (in previous 364d); Numerator definition: No. of denominator patients with trimethoprim issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P027)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P027- Denominator definition: No. of patients with digoxin issued in the last 84d; Numerator definition: No. of denominator patients with latest potassium <3.0 mmol/L (in previous 364 d)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P028)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P028- Denominator definition: No. of patients with CKD stage 4 or 5 or latest eGFR <30 ml/min (in previous 364d); Numerator definition: No. of denominator patients with metformin issued in last 84d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P029)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P029- Denominator definition: No. of patients Aged 75 or older without heart failure; Numerator definition: No. of denominator patients with last systolic blood pressure (SBP) <110 and last diastolic blood pressure (DBP)<65 and any of the following issued in last 56d: ACEI, ARB, beta blocker, thiazide, calcium channel blocker, alpha blocker, oral nitrate, centrally acting antihypertensive drug
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P030)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P030- Denominator definition: No. of patients with dementia and hypertension; Numerator definition: No. of denominator patients with Last SBP <130 and last DBP<75 and two or more of the following issued in last 56d: ACEI, ARB, beta blocker, thiazide, calcium channel blocker, alpha blocker, oral nitrate, centrally acting antihypertensive drug
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P031)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P031- Denominator definition: No. of patients aged 65 years or older with dementia; Numerator definition: No. of denominator patients with antipsychotic issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P032)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P032- Denominator definition: No. of patients who are female and have previous venous thromboembolism; Numerator definition: No. of denominator patients with Oestrogen issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P033)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P033- Denominator definition: No. of patients with atrial fibrillation (AF) and C(ardiac failure)H(ypertension)A(ge)D(iabetes)S(troke/TIA)VASc(ular disease history) score >=3; Numerator definition: No. of denominator patients with NO oral anticoagulant issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P034)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P034- Denominator definition: No. of patients with asthma without chronic obstructive pulmonary disease (COPD) and a short acting beta agonist (SABA) issued in last 84d; Numerator definition: No. of denominator patients with non-cardio-selective beta blocker issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P035)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P035- Denominator definition: No. of patients aged 75 years and older and an oral steroid issued in last 84d and in the last 85 to 168 days; Numerator definition: No. of denominator patients with no bisphosphate, vitamin D or calcium issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P036)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P036- Denominator definition: No. of patients with dementia; Numerator definition: No. of denominator patients with two or more drugs with significant sedating or anticholinergic effects issued in previous 56d (excluding drugs only used for epilepsy)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P037)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P037- Denominator definition: No. of patients with no dementia and aged 65 to 74 years; Numerator definition: No. of denominator patients with THREE or more drugs with significant sedating or anticholinergic effects issued in previous 56d (excluding drugs only used for epilepsy)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P038)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P038- Denominator definition: No. of patients with no dementia and aged 75 years or older; Numerator definition: No. of denominator patients with two or more drugs with significant sedating or anticholinergic effects (excluding drugs only used for epilepsy)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P039)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P039- Denominator definition: No. of patients with opioid issued in last 84d; Numerator definition: No. of denominator patients issued an opioid in last 56d and issued opioids at an average daily dose equivalent to >180mg morphine per day over the previous 182d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P040)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P040- Denominator definition: No. of patients with gabapentin or pregabalin issued in last 84d; Numerator definition: No. of denominator patients issued gabapentin or pregabalin in the last 56d and issued gabapentin or pregabalin at an average daily dose of >4800mg gabapentin per day over the previous 182d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P041)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P041- Denominator definition: No. of patients with lithium issued in last 84d; Numerator definition: No. of denominator patients with an NSAID issued in the last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P042)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P042- Denominator definition: No. of patients with lithium issued in last 84d; Numerator definition: No. of denominator patients with thiazide diuretic issued in previous 56d and no thiazide diuretic issued in previous 57 to 112 days
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P043)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P043- Denominator definition: No. of patients with levodopa issued in last 84d; Numerator definition: No. of denominator patients with prochlorperazine issued in last 56d and previous 57 to 112d or metoclopramide issued in last 56d and previous 57 to 112d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P044)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P044- Denominator definition: No. of patients aged 65 years or older; Numerator definition: No. of denominator patients with metoclopramide issued in last 56 and in the previous 57 to 112d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P045)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P045- Denominator definition: No. of patients with a history of breast cancer; Numerator definition: No. of denominator patients with oestrogen issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P046)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P046- Denominator definition: No. of female patients aged 60 years or older; Numerator definition: No. of denominator patients with estrogen issued in last 56d
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P047)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P047- Denominator definition: No. of patients with thiazide or a loop diuretic issued in the last 84d; Numerator definition: No. of denominator patients with latest potassium <3.0 mmol/L (in previous 364 d)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P048)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P048- Denominator definition: No. of patients with selective serotonin reuptake inhibitor (SSRI), thiazide or loop diuretic issued in last 84d; Numerator definition: No. of denominator patients with latest sodium <130 mmol/l (in previous 364 days)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P049)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P049- Denominator definition: No. of patients with a thiazide issued in last 84d; Numerator definition: No. of denominator patients with latest calcium >2.65 mmol/L (in previous 364 days)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Individual indicators (P050)
Time Frame: Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
P050- Denominator definition: No. of patients with ACEI or ARB, potassium sparing diuretic, aldosterone antagonist, aliskiren or potassium supplement issued in previous 84d; Numerator definition: No. of denominator patients with latest potassium >5.5mmol/L (in previous 364 days)
|
Measured at intervals of 8 weeks over a period of 18 months prior to and subsequent to the start date. The measurement on the start date will be excluded from analyses to account for the availability of a test version of the P-DQIP tool since Sept 2018
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tobias Dreischulte, University of Dundee/NHS Tayside
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2018PS02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medication Safety
-
Anne Estrup OlesenAalborg University; University College of Northern Denmark; Aalborg KommuneRecruitingPatient Safety | Medication SafetyDenmark
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminatedPatient Empowerment | Patient Safety | Medication SafetyNetherlands
-
University of Massachusetts, WorcesterAgency for Healthcare Research and Quality (AHRQ); Reliant Medical GroupCompleted
-
Karen C. Nanji,M.D.,M.P.H.University of California, San Francisco; University of Toronto; University of... and other collaboratorsNot yet recruitingPerioperative Medication Safety
-
Cedars-Sinai Medical CenterAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitation
-
Sykehuset Innlandet HFNorwegian University of Science and TechnologyCompletedPatient Safety | Medication AdministrationNorway
-
University of NottinghamUniversity of ManchesterCompletedInappropriate Prescribing | Patient Safety | Medication ErrorsUnited Kingdom
-
Agency for Healthcare Research and Quality (AHRQ)CompletedImpact of Electronic Prescribing on Medication SafetyUnited States
-
University Hospital, GhentCompletedPatient Safety | Medication ErrorsBelgium
-
Massachusetts General HospitalAgency for Healthcare Research and Quality (AHRQ)CompletedQuality Improvement | Patient Safety | Medication Errors | Medical Records Systems, ComputerizedUnited States
Clinical Trials on P-DQIP
-
University of DundeeNHS Tayside; NHS FifeCompleted
-
Coloplast A/SCompleted
-
University of OregonOregon Social Learning CenterCompletedChild BehaviorUnited States
-
Campus Bio-Medico UniversityCompletedVascular Access ComplicationItaly
-
Medtronic Cardiac Rhythm and Heart FailureTerminatedCongestive Heart Failure | Systolic Heart Failure | Left Bundle Branch BlockUnited States, Sweden, India, Russian Federation, United Kingdom
-
University of ManchesterRoyal Children's HospitalCompleted
-
Synthes USA HQ, Inc.Terminated
-
Abbott Medical DevicesCompleted
-
Fisher and Paykel HealthcareCompletedObstructive Sleep Apnea | Sleep Disordered BreathingNew Zealand
-
Coloplast A/SCompleted